Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
August 05, 2024 08:00 ET
|
Design Therapeutics, Inc.
Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials Active Research Pipeline with Programs Progressing in Myotonic Dystrophy...
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
May 08, 2024 16:05 ET
|
Design Therapeutics, Inc.
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study...
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024 06:30 ET
|
Design Therapeutics, Inc.
CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced...
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
March 19, 2024 16:01 ET
|
Design Therapeutics, Inc.
New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025...
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
March 12, 2024 06:30 ET
|
Design Therapeutics, Inc.
CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today...
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
November 13, 2023 16:05 ET
|
Design Therapeutics, Inc.
Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Turnaround Current Cash and Securities of ~$290M Support Extended Five-Year Operating Runway Through 2028 ...
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
August 14, 2023 16:05 ET
|
Design Therapeutics, Inc.
Initial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Showed Significant Increase in FXN mRNA Levels in Skeletal Muscle Company Expects to Resume a Multiple Dose...
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
August 14, 2023 16:01 ET
|
Design Therapeutics, Inc.
DT-216 Resulted in a Significant Increase in FXN mRNA Levels in Skeletal Muscle of FA Patients Treatment Generally Well-Tolerated; Injection Site Reactions Attributable to Current Formulation...
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
May 31, 2023 06:30 ET
|
Design Therapeutics, Inc.
CARLSBAD, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,...
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
May 09, 2023 16:05 ET
|
Design Therapeutics, Inc.
Initial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Expected in the Third Quarter of 2023 Progress Across GeneTAC™ Small Molecule Pipeline with IND Submissions...